Squamous cell carcinoma of the tongue and oropharynx is characterized by significant clinical and biological heterogeneity, highlighting the need for reliable prognostic and predictive biomarkers. This review analyzes current evidence regarding the significance of programmed death-ligand 1 (PD-L1) expression and immune microenvironment characteristics in these malignancies. PD-L1 has been shown to play a central role in tumor immune evasion; however, its prognostic value remains controversial and appears to depend on human papillomavirus (HPV) status, tumor immune contexture, and methodological approaches used for assessment. More consistent associations with clinical outcomes have been demonstrated for immune infiltration parameters, including high densities of CD8+ T lymphocytes, abundant tumor-infiltrating lymphocytes, and a favorable balance between effector and regulatory immune cells. The combined assessment of PD-L1 expression, immune microenvironment features, and HPV status may improve patient stratification and facilitate personalized treatment strategies. Further studies are required to standardize PD-L1 evaluation methods and to develop integrated prognostic models incorporating molecular and immunological biomarkers.
Background: Lung cancer remains the leading cause of cancer mortality world-wide, underscoring the need for non-invasive early diagnostic tools. IP-10, a cytokine involved in inflammation and angiogenesis, is a promising candidate. The present study aims to assess the relevance of IP-10 in lung cancer early diagnosis. Methods: In this cross-sectional study, we measured serum IP-10 levels using Luminex assays in 52 treatment-naïve lung cancer patients without comorbidities and 14 healthy controls. Based on the non-normal distribution of data, group comparisons were performed using Wil-coxon rank-sum tests. Multivariate linear regression was used to adjust for cofounders. Results: IP-10 levels were significantly elevated in lung cancer patients compared to healthy controls (median: 189.69 pg/mL vs. 108.78 pg/mL, p = 0.001). This significance persisted in the early-stage subgroup (stages 0-IIA; median: 192.49 pg/mL vs. 108.78 pg/mL, p = 0.001), even after multivariate adjustment (p = 0.018). Levels peaked in evolved early-stage disease (median: 241.42 pg/mL) before declining in advanced stages, while remaining elevated above controls. Discussion: The rise in IP-10 levels in early-stage lung cancer patients emphasizes its potential to serve as an early diagnostic biomarker. Meanwhile, the peak-and-decline pattern during phases of disease is consistent with its postulated dual role in early antitumor immunity and later tumor promotion. Conclusion: IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.